A detailed history of Virtus ETF Advisers LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 6,921 shares of RGNX stock, worth $67,272. This represents 0.04% of its overall portfolio holdings.

Number of Shares
6,921
Previous 4,159 66.41%
Holding current value
$67,272
Previous $87,000 8.05%
% of portfolio
0.04%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $31,790 - $59,465
2,762 Added 66.41%
6,921 $80,000
Q1 2024

May 15, 2024

SELL
$12.17 - $24.61 $3,504 - $7,087
-288 Reduced 6.48%
4,159 $87,000
Q4 2023

Feb 15, 2024

SELL
$12.89 - $20.82 $7,450 - $12,033
-578 Reduced 11.5%
4,447 $79,000
Q3 2023

Nov 07, 2023

SELL
$16.46 - $19.99 $8,197 - $9,955
-498 Reduced 9.02%
5,025 $82,000
Q2 2023

Aug 14, 2023

BUY
$17.23 - $21.71 $21,813 - $27,484
1,266 Added 29.74%
5,523 $110,000
Q1 2023

May 15, 2023

SELL
$18.08 - $24.55 $29,578 - $40,163
-1,636 Reduced 27.76%
4,257 $80,000
Q4 2022

Feb 14, 2023

BUY
$20.4 - $24.73 $13,157 - $15,950
645 Added 12.29%
5,893 $133,000
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $869 - $1,366
39 Added 0.75%
5,248 $139,000
Q2 2022

Aug 12, 2022

BUY
$19.35 - $35.04 $7,333 - $13,280
379 Added 7.85%
5,209 $129,000
Q1 2022

May 16, 2022

SELL
$24.62 - $34.31 $6,942 - $9,675
-282 Reduced 5.52%
4,830 $160,000
Q4 2021

Feb 14, 2022

SELL
$30.19 - $40.28 $16,544 - $22,073
-548 Reduced 9.68%
5,112 $167,000
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $8,785 - $13,795
-302 Reduced 5.07%
5,660 $237,000
Q2 2021

Aug 10, 2021

SELL
$32.46 - $40.48 $49,209 - $61,367
-1,516 Reduced 20.27%
5,962 $232,000
Q1 2021

May 17, 2021

BUY
$33.61 - $49.95 $4,671 - $6,943
139 Added 1.89%
7,478 $255,000
Q4 2020

Feb 12, 2021

SELL
$26.52 - $49.35 $37,658 - $70,077
-1,420 Reduced 16.21%
7,339 $333,000
Q3 2020

Nov 13, 2020

SELL
$27.01 - $40.26 $32,222 - $48,030
-1,193 Reduced 11.99%
8,759 $241,000
Q2 2020

Aug 05, 2020

BUY
$27.75 - $43.44 $47,619 - $74,543
1,716 Added 20.84%
9,952 $367,000
Q1 2020

May 14, 2020

SELL
$21.5 - $54.2 $25,800 - $65,040
-1,200 Reduced 12.72%
8,236 $267,000
Q4 2019

Feb 13, 2020

BUY
$34.54 - $44.87 $145,206 - $188,633
4,204 Added 80.35%
9,436 $387,000
Q3 2019

Nov 12, 2019

SELL
$31.84 - $50.88 $9,297 - $14,856
-292 Reduced 5.29%
5,232 $186,000
Q2 2019

Aug 13, 2019

SELL
$42.0 - $59.29 $13,314 - $18,794
-317 Reduced 5.43%
5,524 $284,000
Q1 2019

May 14, 2019

SELL
$40.82 - $62.45 $27,798 - $42,528
-681 Reduced 10.44%
5,841 $335,000
Q4 2018

Feb 05, 2019

SELL
$39.11 - $75.15 $75,482 - $145,039
-1,930 Reduced 22.83%
6,522 $274,000
Q3 2018

Nov 14, 2018

SELL
$65.0 - $82.15 $392,600 - $496,186
-6,040 Reduced 41.68%
8,452 $638,000
Q2 2018

Aug 10, 2018

SELL
$27.2 - $74.35 $328,249 - $897,255
-12,068 Reduced 45.44%
14,492 $1.04 Million
Q1 2018

May 14, 2018

BUY
$24.05 - $37.5 $344,131 - $536,587
14,309 Added 116.8%
26,560 $793,000
Q4 2017

Feb 14, 2018

SELL
$26.0 - $34.6 $130,520 - $173,692
-5,020 Reduced 29.07%
12,251 $407,000
Q3 2017

Nov 14, 2017

BUY
$18.0 - $32.95 $28,440 - $52,061
1,580 Added 10.07%
17,271 $569,000
Q2 2017

Aug 14, 2017

BUY
N/A
15,691
15,691 $310,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $420M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.